Studies

Anokion/Pfizer KAN-101-02 Celiac

Internal Medicine Gastroenterology Digestive Disease Adult Subjects

This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participants with Celiac Disease (CeD).